Clinical Trials

163 enrolled

Stomach Neoplasms

NCT06625775 2026-03-18

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

BreastGastrointestinalThoracic

392 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT06917079 2026-03-18

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

387 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT07221357 2026-03-17

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Phase 2/3 Recruiting

990 enrolled

Colorectal Neoplasms

NCT04808323 2026-03-16

MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer

22 enrolled

Rectal Neoplasms

NCT06179160 2026-03-16

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

710 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT07284849 2026-03-16

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

700 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT06663319 2026-03-13

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

220 enrolled

Gastrointestinal Neoplasms, Colorectal Neoplasms

NCT05733689 2026-03-10

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

20 enrolled

Gastroesophageal Adenocarcinoma

NCT07221149 2026-03-04

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Phase 2/3 Recruiting

690 enrolled

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT04215731 2026-03-03

FOBEAR

582 enrolled

Rectal Neoplasms

NCT04929223 2026-03-03

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

542 enrolled

Phase 1/2 Active not recruiting

Colorectal Neoplasms

NCT04068610 2026-03-02

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

61 enrolled 35 charts

Colonic Neoplasms

NCT06346197 2026-03-02

CIME

132 enrolled

Phase EARLY_PHASE1 Recruiting

Neoplasm Metastasis, Stomach Neoplasms

NCT07193862 2026-02-27

Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis

10 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Colorectal Cancer Metastatic

NCT07318389 2026-02-27

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

100 enrolled

Colorectal Neoplasms

NCT07323576 2026-02-09

INAVO-CRC

Phase 2 Withdrawn

Colorectal Neoplasms

NCT00208260 2026-02-05

Intensified Chemotherapy in CRC After Resection of Liver Metastases

Phase 2/3 Completed

124 enrolled

Colorectal Neoplasms

NCT05855200 2026-01-23

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

892 enrolled

Colonic Neoplasms

NCT07265674 2026-01-23

Beacon-BTC

480 enrolled

Phase 2 Not yet recruiting

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07353827 2026-01-20

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

36 enrolled

Phase 2 Active not recruiting

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT06106308 2026-01-12

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

113 enrolled

Phase EARLY_PHASE1 Active not recruiting

Colorectal Neoplasms

NCT05108428 2026-01-08

Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma

20 enrolled

Phase 1 Active not recruiting

Colonic Neoplasms, Rectal Neoplasms

NCT06838338 2026-01-08

JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC

30 enrolled

Colorectal Neoplasms

NCT07309289 2025-12-30

NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer

144 enrolled

Colorectal Neoplasms

NCT05171166 2025-12-18

Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.

Phase 2/3 Terminated

18 enrolled

Carcinoma, Hepatocellular

NCT06154538 2025-11-28

Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer

170 enrolled

Locally Advanced Colorectal Carcinoma

NCT06846346 2025-11-28

GRACIE

88 enrolled

Phase 3 Not yet recruiting

Adenocarcinoma Of Esophagus, Adenocarcinoma, Neoplasm Metastasis, Neoplasms

NCT06783491 2025-11-24

FOXHIPECT4

1,083 enrolled

Colorectal Neoplasms

NCT02967289 2025-11-17

IROCAS

Phase 3 Completed

792 enrolled

Colonic Neoplasms, Neoplasms

NCT06529718 2025-11-17

SEVILLA

72 enrolled

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT04656041 2025-11-14

Folfox+Irinotecan+Chemort In Esophageal Cancer

40 enrolled

Gastroesophageal Junction Adenocarcinoma

NCT05033522 2025-10-23

ALIVE

Phase 2/3 Suspended

150 enrolled

Phase 2 Active not recruiting

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04595266 2025-09-29

LIVERPEARL

48 enrolled

Colorectal Neoplasms

NCT07192185 2025-09-25

Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab

30 enrolled

Carcinoma, Hepatocellular

NCT06253611 2025-09-22

BIG

120 enrolled

Phase 3 Active not recruiting

Stomach Neoplasms

NCT04919226 2025-09-10

COMPOSE

259 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT06936527 2025-09-03

XS-03-II201

Phase 1/2 Enrolling by invitation

102 enrolled

Colorectal Neoplasms

NCT05024097 2025-08-27

PANTHER

43 enrolled

Rectal Neoplasms

NCT05480306 2025-08-03

DeFianCe

Phase 2 Completed

188 enrolled

Phase 3 Not yet recruiting

Colonic Neoplasms, Colorectal Neoplasms

NCT07074353 2025-07-25

CinClare-2

360 enrolled

Locally Advanced Rectal Cancer

NCT06893887 2025-07-02

ICT-HCC

Phase NA Recruiting

300 enrolled

Carcinoma, Hepatocellular

NCT03186326 2025-06-29

SAMCO

Phase 2 Completed

132 enrolled

Colorectal Neoplasms

NCT03584711 2025-06-29

OPTIPRIME

Phase 2 Completed

118 enrolled

Phase 2 Active not recruiting

Colorectal Neoplasms

NCT05712356 2025-06-06

BOLSTER

67 enrolled

Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Disease Progression

NCT06991465 2025-05-28

Hypo-OPRA

35 enrolled

Colorectal Neoplasms

NCT06907342 2025-05-25

COSENSE-1

148 enrolled

Phase 2 Not yet recruiting

Colorectal Neoplasms

NCT06972498 2025-05-15

A Prospective Multicenter Study: Ivosimab + Chemotherapy as Neoadjuvant for Resectable pMMR/MSS CRC Liver Mets

35 enrolled

Phase 2 Not yet recruiting

Colorectal Cancer With Liver Metastasis

NCT06946849 2025-04-27

SED-RO-ICC

76 enrolled